## NTI drug with high CV? [Power / Sample Size]

Hi Mikalai,

❝ What would be a sample size for a BE study when the CV of the drug is 30% but bioequivalence should be in range 90_110%?

Unless the drug belongs to the last generation anticoagulants (dabigatran, rivaroxaban) that's a contradiction. NTIDs show low variability. Otherwise, there would have been serious problems in phase III: toxicity, lacking efficacy – no approval – end of story.
BTW, the acceptance limits for NTIDs in the EEA are 90.00–111.11%.

❝ Our assumption is around 400 subject if the design is standard, and 200 if the design is replicative

library(PowerTOST) sampleN.TOST(CV = 0.3, theta1 = 0.9, design = "2x2x2") sampleN.TOST(CV = 0.3, theta1 = 0.9, design = "2x2x4")

Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

22,417 posts in 4,692 threads, 1,596 registered users;
21 visitors (0 registered, 21 guests [including 10 identified bots]).
Forum time: 10:35 CET (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
Ing. Helmut Schütz